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Background: Some patients experience statin-induced side effects or prefer
nutraceutical approaches for the treatment of dyslipidemia. This has led to a search
for alternative therapeutic approaches for dyslipidemia management. In recent studies
Citrus bergamia (known as Bergamot) juice was able to reduce serum levels of lipids.
Such benefit may be attributed to high amounts of flavonoids contained in Bergamot fruit
juice (neoeriocitrin, neohesperidin, naringin). The aim of the present study was to fully
investigate the effects of a Bergamot extract on cardio-metabolic parameters, including
plasma lipids, atherogenic lipoproteins and subclinical atherosclerosis.
Methods: Eighty subjects (42 men and 38 women, mean age: 55 ± 13 years)
with moderate hypercholesterolemia [e.g., with plasma LDL-cholesterol concentrations
between 160 and 190 mg/dl (between 4.1 and 4.9 mmol/l)] were included. A Bergamot-
derived extract (Bergavit©R ) was given at a fixed dose daily (150 mg of flavonoids,
with 16% of neoeriocitrin, 47% of neohesperidin and 37% of naringin) for 6 months.
Lipoprotein subfractions were assessed by gel electrophoresis. With this methodology
low density lipoprotein (LDL) subclasses are distributed as seven bands (LDL-1 and
-2 as large LDL, and LDL-3 to -7 as atherogenic small, dense LDL). Subclinical
atherosclerosis was assessed by carotid intima-media thickness (cIMT) using B-mode
ultrasound.
Results: After 6 months, Bergavit©R reduced total cholesterol (from 6.6 ± 0.4 to
5.8 ± 1.1 mmol/l, p < 0.0001), triglycerides (from 1.8 ± 0.6 to 1.5 ± 0.9 mmol/l,
p = 0.0020), and LDL-cholesterol (from 4.6 ± 0.2 to 3.7 ± 1.0 mmol/l, p < 0.0001),
while HDL- cholesterol increased (from 1.3 ± 0.2 to 1.4 ± 0.4 mmol/l, p < 0.0007).
In addition, a significant increase in LDL-1 (from 41.2 ± 0.2 to 49.6 ± 0.2%,
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p < 0.0001) was accompanied by decreased small, dense LDL-3, -4, and 5 particles
(from 14.5 ± 0.1 to 9.0 ± 0.1% p < 0.0001; 3.2 ± 0.1 to 1.5 ± 0.1% p = 0.0053;
0.3 ± 0.0% to 0.1 ± 0.0% p = 0.0133, respectively). cIMT also decreased from
1.2 ± 0.4 to 0.9 ± 0.1 mm (p < 0.0001).
Conclusion: This is the first study investigating the effects of Bergamot flavonoids
supplementation on cardio-metabolic risk in dyslipidemic subjects. Bergavit©R (Bergamot
juice extract) supplementation significantly reduced plasma lipids and improved the
lipoprotein profile. cIMT was also reduced significantly over a relatively short time frame
of 6 months.
Keywords: Bergamot, cardiovascular risk, carotid IMT, hypercholesterolemia, LDL subclasses
INTRODUCTION
Statins are the most commonly used class of drugs [3-hydroxy-
3-methylglutaryl Co-enzyme A (HMG-CoA) reductase
inhibitors] to lower serum cholesterol levels, with favorable
eﬀects on both plasma lipids and lipoproteins (Rizzo and
Berneis, 2006a,b; Rizzo et al., 2007; Nikolic et al., 2013;
Garcia-Rios et al., 2014). To this regard, particular attention
has been focused on low density lipoprotein cholesterol
(LDL-C) since several lines of evidences suggest that they
are directly and independently associated to cardiovascular
(CV) risk (Adhyaru and Jacobson, 2015). However, despite
several advances in the pharmacological strategies for
maintaining lipid homeostasis, some treated patients do
not reach their LDL-C goal and remain at increased CV
risk (Alagona and Ahmad, 2015), while others experience
intolerance especially at high doses of statins (i.e., myopathy,
rhabdomyolysis, hepatotoxicity, growth retardation in pediatric
population; Banach et al., 2015a,b). In such situations certain
alternative therapeutic approaches including the use of dietary
supplements and nutraceuticals may be prudent (Patti et al.,
2015).
A number of supplements for dyslipidemia are available in
the market with beneﬁcial eﬀects on plasma lipids, although
their impact on CV risk remains largely unknown (Mannarino
et al., 2014). In this context, several studies have demonstrated
multiple health-related properties of the Citrus ﬂavonoids on
CV protection (Benavente-Garcia and Castillo, 2008). Bergamot
is the common name of the fruit Citrus bergamia Risso
(family Rutaceae) which diﬀers from other Citrus fruits in the
composition and content of several distinct ﬂavonoids, such as
neoeriocitrin, neohesperidin, naringin (Dugo et al., 2005; Nogata
et al., 2006). Preclinical and clinical studies indicated a hypo-
cholesterolemic property of C. bergamia ﬂavonoids (Trombetta
et al., 2010; Mollace et al., 2011; Sakurada et al., 2011; Graziano
et al., 2012; Di Donna et al., 2014; Risitano et al., 2014).
However, the eﬀects of Bergamot ﬂavonoids on lipoprotein sizes
and subclasses are still largely unknown. A Bergamot juice
derived ﬂavonoid extract, Bergavit R© (Bionap, Italy) contains
about 28–30 % of ﬂavonoids (including naringin, neoeriocitrin,
and neohesperidin).
The aim of the present study was to elucidate the eﬀects
of Bergavit R© supplementation on cardio-metabolic parameters,
including plasma lipids, atherogenic lipoproteins and subclinical




A total of 80 subjects (42 men and 38 women, mean age:
55 ± 13 years) with moderate hypercholesterolemia [e.g., with
plasma LDL-C concentrations between 160 and 190 mg/dl
(between 4.1 and 4.9 mmol/l)] were included in the present
study. All subjects were referred to our Unit of Diabetes and
CV Prevention for a clinical evaluation and were naïve to statin
treatment. The study design included a medical examination,
anthropometric data collection, biochemical analyses, and eco-
color-Doppler examination of carotid arteries. The procedures
used were in agreement with the Helsinki Declaration of 1975
as revised in 1983, and were approved by the Ethics Council
of the University of Palermo, Italy. The study is registered in
clinicaltrials.gov (NCT02205567).
All subjects gave informed consent before entering the study.
At admission they underwent a medical examination and were
excluded from the study if they had clinical evidence of severe
hepatic or renal diseases. All subjects received daily Bergamot
derived ﬂavonoid extract, Bergavit R© (Bionap, Italy), containing
150 mg of ﬂavonoids, with 16% of neoeriocitrin, 47% of
neohesperidin, and 37% of naringin (as determined by Bionap,
see Figure 1), for 6 months. All medical and biochemical
procedures were performed at baseline and after 6 months of
supplementation.
Analytical Method: Determination of
Flavanones in BergavitR©
Instrumentation and Analytical Conditions
The analyses were carried out by Bionap (Catania, Italy)
on a Shimadzu LC system, coupled to an SPD-M20A
photodiode array detector (UV-DAD). The chromatographic
separation was performed, also by Bionap (Catania, Italy),
on a Kinetex C18 column (150 mm × 4.6 mm id-5 μm
ip; Phenomenex) thermostated at 20◦C; the mobile phases
used were the following: Water (HPLC grade)/0.1% Formic
Acid (eluent A) and Acetonitrile (HPLC grade)/0.1% Formic
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FIGURE 1 | The components of Bergavit R© separated by high-performance liquid chromatography (HPLC-DAD Analysis 280 nm), as determined by
Bionap. The chromatographic analyses are determined on a Shimadzu LC system by Bionap.
Acid (eluent B) (Sigma–Aldrich, Milan, Italy) using the
following elution gradient: 0–5 min 13% B; 5–35 min 25%
B; 35–38 min 90% B; 38–43 min 90% B; 43–45 min 13%
B; 45–50 min 13% B. The ﬂow was 1.0 mL/min and the
injection volume was 5 μL (autosampler). The UV-Vis
spectra were acquired on the range 190–800 nm, while the
chromatograms were extracted at 280 nm, the λmax for
ﬂavanones compounds. The quantiﬁcation of ﬂavanones
compounds was carried out making the calibration curves for
neoeriocitrin, naringin, and noehesperidin. Sample was dissolved
in water and ﬁltered under 0.45 μmmembrane ﬁlter prior HPLC
injection.
Biochemical Analyses
At baseline and after 6 months of Bergavit R© supplementation
serum samples were collected after a 14 h overnight fast
and stored for subsequent analysis. Total cholesterol (TC),
triglycerides (TG), and high density lipoprotein cholesterol
(HDL-C) were measured by routine laboratory methods, while
LDL-C was calculated using the Friedewald formula.
We assessed a total of 11 distinct lipoprotein subclasses
including very low-density lipoproteins (VLDL), 3 intermediate
density-lipoprotein (IDL A, IDL B and IDL C) and 7
LDL subfractions. LDL subclasses were assessed by non-
denaturing, linear polyacrylamide gel electrophoresis (Lipoprint,
Quantimetrix Corporation, USA), in Palermo, Italy, as previously
reported (Berneis et al., 2010; Scichilone et al., 2013; Rizzo et al.,
2014). This is the only Food and Drug Administration-approved
diagnostic tool for lipoprotein subfraction testing (Mikhailidis
et al., 2011a). Brieﬂy, the procedure was performed for 60 min
with 3 mA for each gel tube. Each electrophoresis chamber
involved two quality controls. The LDL bands in the sample
were identiﬁed according to their mobility using VLDL as the
starting reference point and HDL as the leading reference point.
The electrophoresed gels were scanned using a digital scanner
and a Mac computer (Apple Computer Inc, USA). The relative
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area for each lipoprotein band was determined and multiplied
by the TC concentration of the sample and expressed in mg/dl.
LDL subclasses were distributed as seven bands (LDL1 to LDL7,
respectively; Berneis et al., 2010; Scichilone et al., 2013; Rizzo
et al., 2014). LDL1 and -2 are deﬁned as large LDL, while LDL3 to
-7 as small, dense LDL (Mikhailidis et al., 2011a).
Color Doppler Ultrasound of Carotid
Arteries
B-mode real-time ultrasound was performed at baseline and
after 6 months of therapy to evaluate the arterial wall thickness
in the carotid arteries. All examinations were performed in
Palermo, Italy, by a single examiner (A.M.P.) using a single
sonographer (Medison SonoAce Pico, with a probe of 7.5–
10.0 MHz) in a blinded manner; the examiner did not have access
to previous scans. The ultrasound examination was performed in
a standardized manner with ﬁxed angles of insonation.
As previously reported (Corrado et al., 2006), subjects were
examined in the supine position, and each carotid wall or segment
was examined to identify the thickest intimal-medial site. Each
scan of the common carotid artery began just above the clavicle,
and the transducer was moved to the carotid bifurcation and
along the internal carotid artery. Three segments were identiﬁed
and measured in anterior and posterior planes on each side:
the distal 1.0 cm of the common carotid artery proximal to the
bifurcation, the bifurcation itself, and the proximal 1.0 cm of the
internal carotid artery. At each of these sites we determined the
carotid intima-media thickness (cIMT), deﬁned as the distance
between the echogenic line representing the intimal blood
interface and the outer echogenic line representing the adventitial
junction. The maximum cIMT value was used for analysis and
determined as the mean of the maximum cIMT of near- and far-
wall measurements of both the left and right side arteries for each
of the three arterial segments.
Statistical Analysis
Statistical analysis was performed using SPSS software (V.17.0
for Windows, SPSS Inc., Chicago, IL, USA). Univariate analysis
was performed using paired t-test. We used ANOVA to test the
relationships between the therapeutical changes in LDL-C and
baseline plasma LDL-C, expressed in quartiles. We calculated the
quartiles as following: the ﬁrst quartile (Q1) includes subjects
with the lowest LDL-C baseline levels (between the lowest value
and top 25%), the second quartile (Q2) includes subjects with
baseline levels between top 25% and top 50%, the third quartile
(Q3) includes subjects with baseline levels between top 50% and
top 75%, and the forth quartile (Q4) includes subjects with the
highest LDL-C baseline levels (between top 75% and the highest
value). Correlation analysis was performed using the Spearman
rank correlation method.
RESULTS
Baseline characteristics of all subjects are shown in Table 1. None
of them had to discontinue the supplementation and no adverse
events were recorded.
TABLE 1 | Baseline characteristics of all subjects (n = 80).
Age (years) 55 ± 13
Women, n (%) 38 (48)
Dyslipidemia duration (years) 5 ± 8
Smoking habit, n (%) 20 (25)
Family history of cardiovascular disease, n (%) 51 (64)
Diabetes, n (%) 42 (53)
Hypertension, n (%) 48 (60)
Obesity, n (%) 28 (35)
After 6 months of Bergavit R© supplementation (data not
shown) anthropometric parameters slightly improved (body
weight, waist circumference, and body mass index), but the
diﬀerences did not achieve the statistical signiﬁcance. As shown
in Table 2, plasma lipids signiﬁcantly improved with a decrease
in TC, LDL-C (p < 0.0001 for both) and TG (p = 0.0020),
while HDL-C increased (p = 0.0007). Box plots of  LDL-
C (%) based on quartiles of baseline plasma LDL-C levels
are shown in Figure 2. A stronger reduction in plasma LDL-
C level was achieved in subjects with higher baseline LDL-C
levels (p = 0.004 for trend). In addition, large LDL1 particles
increased by 20% (p < 0.0001), while small, dense LDL3,
LDL4, and LDL5 decreased by 38, 53, and 67% (p < 0.0001,
p = 0.0053, and p = 0.0133, respectively). This lead to a
decreased LDL peak particle size (p < 0.0001). In addition
(data not shown), large, medium, and small IDL signiﬁcantly
increased after 6 months of Bergavit R© supplementation, with the
greatest increase in larger IDL-C subclasses, while no signiﬁcant
diﬀerences were found for VLDL particles. A representative
lipoprotein proﬁle for one subject before and after Bergavit R©
supplementation is shown in Figure 3. Further, cIMT, as a
marker of subclinical atherosclerosis, decreased after 6 months
of Bergavit R© supplementation from 1.2 ± 0.4 to 0.9 ± 0.1 mm
(25%; p < 0.0001; see Table 2).
Finally, we performed a correlation analysis (data not shown)
in order to assess potential associations between the observed
changes in all evaluated parameters. A signiﬁcant positive
association was found between LDL-C and both TC (r = +0.908;
p < 0.0001) and waist circumference (r = +0.273; p = 0.0143).
Change in cIMT was associated with changes in the smallest
LDL5 particles (r = +0.242; p = 0.031).
DISCUSSION
The ﬁndings of the present study indicate that Bergavit R©
supplementation has beneﬁcial eﬀects on lipid levels
including atherogenic LDL particles in subjects with
moderate hypercholesterolemia. After 6 months of Bergavit R©
supplementation lipid levels (TC, TG, and LDL-C) decreased,
while the atherogenic lipid pattern improved (with increased
presence of large and decreased presence of small, dense LDL
particles). Our ﬁndings are somewhat consistent with previous
studies (Mollace et al., 2011; Gliozzi et al., 2013, 2014). However,
we have shown for the ﬁrst time that supplementation with this
extract reduced cIMT. This is of high clinical importance, since it
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TABLE 2 | Effects of Bergavit R© (150 mg of flavonoids, with 16% of neoeriocitrin, 47% of neohesperidin, and 37% of naringin, daily) on plasma lipids, LDL
subclasses and carotid intima-media thickness (IMT) in subjects with moderate hypercholesterolemia after 6 months of supplementation.
Baseline After 6 months p % Change
Total cholesterol (mmol/l) [mg/dl] 6.6 ± 0.4 [257 ± 15] 5.8 ± 1.1 [223 ± 41] <0.0001 −12
HDL-cholesterol (mmol/l) [mg/dl] 1.3 ± 0.2 [48 ± 10] 1.4 ± 0.4 [52 ± 14] 0.0007 +8
Triglycerides (mmol/l) [mg/dl] 1.8 ± 0.6 [162 ± 54] 1.5 ± 0.9 [136 ± 79] 0.0020 −17
LDL-cholesterol (mmol/l) [mg/dl] 4.6 ± 0.2 [176 ± 8] 3.7 ± 1.0 [144 ± 37] <0.0001 −20
Carotid IMT (mm) 1.2 ± 0.4 0.9 ± 0.1 <0.0001 −25
LDL size (angstrom) 264 ± 5 267 ± 7 <0.0001 +1
LDL-1 (%) 41.2 ± 0.2 49.6 ± 0.2 <0.0001 +20
LDL-2 (%) 40.8 ± 0.1 39.7 ± 0.2 0.4428 −3
LDL-3 (%) 14.5 ± 0.1 9.0 ± 0.1 <0.0001 −38
LDL-4 (%) 3.2 ± 0.1 1.5 ± 0.1 0.0053 −53
LDL-5 (%) 0.3 ± 0.0 0.1 ± 0.0 0.0133 −67
LDL-6 (%) − − − −
LDL-7 (%) − − − −
FIGURE 2 | Box plots of  LDL-C (%) based on quartiles of baseline
plasma LDL-C levels in all subjects (n = 80) after 6 months of
Bergavit R© (150 mg of flavonoids, with 16% of neoeriocitrin, 47% of
neohesperidin, and 37% of naringin, daily) supplementation. LDL-C,
low-density lipoprotein cholesterol.
is largely unknown how dietary supplements and nutraceuticals
impact CV risk. The reduction in cIMT suggests that, consistent
with its impact on LDL-C and small LDL subfractions, Bergavit R©
may favorably impact CV risk in subjects with moderate
hypercholesterolemia. Additional investigation will have to
be performed in order to fully elucidate how the Bergavit R©
components (Bergamot ﬂavonoids) may regulate serum levels of
atherogenic lipoproteins (Dugo et al., 2005; Nogata et al., 2006).
A particular contribution to the lipid-lowering response
appears to be due to neoeriocitrin, neohesperidin, and
naringin, ﬂavonoid glycosides present in Bergamot juice.
Several mechanisms may be advocated in order to explain such
results (Figure 4). Previous reports (Salamone et al., 2012;
Andersen et al., 2014; Bruckbauer and Zemel, 2014; Dong
et al., 2014; Tsutsumi et al., 2014) showed that ﬂavonoids
may activate sirtuin-1 which in turns activates adenosine
monophosphate-activated protein kinase (AMPK)-α which may
serve as a master switch regulator for cell metabolism. Such
pharmacological eﬀect, on one hand, leads to fatty acid oxidation
via carnitine palmitoyltransferase 1 (CPT1) activation (Chang
et al., 2013) and, on the other hand, reduces VLDL synthesis via
the inhibition of hepatocyte nuclear factor 4 (HNF4; Reddy et al.,
1999) and sterol regulatory element-binding protein 1 (SREBP-1;
Quesada et al., 2009). Furthermore, other lipid lowering
molecular mechanisms may include those related to the LDL
receptor. To this regard, previous reports showed that ﬂavonoids
activates protein kinase C (PKC), which in turns triggers a series
of biochemical events, leading to the transcription of the gene
coding for LDL receptor (Kumar et al., 1997), and thus increasing
its expression and concomitantly sequestering circulating LDL
inside the cells. Finally, ﬂavonoids may activate peroxisome
proliferator-activated receptors (PPAR)-γ and thus trigger a
series of molecular mechanisms leading to the translocation
of LDL receptor on the plasma membrane for sequestering
circulating LDL (Farras et al., 2013).
We found a signiﬁcant modiﬁcation in plasma lipoprotein
subfractions after Bergavit R© supplementation that is somewhat
consistent with our previous study where the eﬀects of
another nutraceutical (chitosan) was assessed in patients with
hypertriglyceridemia [TG > 150 mg/dl (>3.9 mmol/l)] (Rizzo
et al., 2014), as well as with other studies that used diﬀerent
nutraceuticals [as reviewed in (Patti et al., 2015)]. In the present
study we found that small dense LDL particles (LDL3, -4, and -5)
decreased, which may decrease CV risk (Mikhailidis et al., 2011a).
In addition, IDL subfractions increased, while VLDL particles did
not change signiﬁcantly. IDL subclasses diﬀer in their ability to
predict CV risk, in the same way as it occurs for LDL subclasses
(Srisawasdi et al., 2013). In this context, in the present study
we found the greatest increase in larger IDL-C subclasses, which
might be less atherogenic compared to the other subspecies.
Our results are somewhat consistent with ﬁndings from a
study that included patients with metabolic syndrome where
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FIGURE 3 | Lipoprotein profile of a rapresentative subject before
(PANEL A) and after (PANEL B) 6 months of Bergavit R© (150 mg of
flavonoids, with 16% of neoeriocitrin, 47% of neohesperidin, and 37%
of naringin, daily) supplementation. Lipoprint color graphs are generated
by lipoprint sytem using Lipoware Clinical Analysis Program.
Bergamot-derived polyphenolic fraction was given before meals
for 120 consecutive days (Gliozzi et al., 2014). In that study,
LDL subfractions were evaluated by nuclear magnetic resonance
spectroscopy, while we used a more detailed method. The eﬀect
of Bergavit R©, observed in our study, may have important clinical
signiﬁcance because of its potential to inﬂuence the quality and
not just the quantity of LDL-C. Small, dense LDL particles
are indeed a recognized risk factor of CV risk, with strong
atherogenic potential. Several mechanisms are involved in the
enhanced atherogenicity of small dense LDL, including the
increased ﬁltration through the endothelium, a reduced LDL
receptor aﬃnity as well as a prolonged circulation time and higher
proteoglycan binding; further, the oxidative modiﬁcation of LDL
is recognized as the key step in the atherothrombotic process,
and small dense LDL exhibit enhanced oxidative susceptibility
and lower levels of antioxidants (Rizzo and Berneis, 2006a,b;
Rizzo et al., 2007; Nikolic et al., 2013; Garcia-Rios et al.,
2014). In addition, in the last years a large number of studies,
including epidemiologic studies as well as clinical intervention
trials, have reported a strong association between CV risk and
small, dense LDL; this topic has been reviewed and discussed
by the European Panel of experts in a Consensus Statement
on the pathophysiology, atherogenicity and clinical signiﬁcance
of LDL subclasses (Mikhailidis et al., 2011a). However, the
mechanism by which the LDL particle shifts to a larger size
cannot be fully discerned from these data. It is likely that the
reductions in both TC and TG induced by Bergavit R© contribute
to this phenomenon. Additionally, it has been shown that
ﬂavonoids may inhibit the oxidation of LDL as well as reduce
oxidative stress in vitro (Fuhrman et al., 1995; Naderi et al.,
2003).
It is widely accepted that elevated LDL-C levels are a major
risk factor for coronary heart disease, and that excessive LDL
in the blood is deposited in the blood vessel walls and becomes
the major component of atherosclerosis plaque lesions (Rizzo
et al., 2010). We found that Bergamot extract supplementation
reduced LDL-C by 20% overall, with a stronger reduction seen
in subjects with higher baseline plasma LDL-C levels. Yet, the
novel ﬁnding of the present study was the beneﬁcial eﬀect
on cIMT. In this context, changes in cIMT correlated with
changes in the smallest LDL5 particles. This ﬁnding might have
important clinical signiﬁcance given that it has been shown that
the smallest, most dense LDL particles are strong predictors of
coronary disease risk (Williams et al., 2003). In addition, smaller
peak LDL particle size predicts an increased risk for myocardial
infarction (Stampfer et al., 1996; Austin et al., 1988) and proposed
mechanisms seem to be related to a greater atherogenicity of
smaller, denser LDL compared to larger, more buoyant LDL
particles (Mikhailidis et al., 2011a,b).
Among dietary supplements it has been shown that
polyphenols can exert beneﬁcial eﬀects on vascular and CVD
protection, such as antioxidant, anti-platelet, anti-inﬂammatory
eﬀects, and may improve endothelial function and contribute
to stabilization of atheromatous plaque (Pandey and Rizvi,
2009). However, more randomized clinical trial data establishing
nutraceuticals’ eﬃcacy for reducing CV risk are needed. For
instance, soy and red yeast rice seem to have eﬀects on CV
events/mortality (Mannarino et al., 2014; Lu et al., 2008), while
some nutraceuticals seem to beneﬁcially aﬀect surrogate markers
of vascular damage, such as arterial IMT, endothelial dysfunction
and arterial stiﬀness (Houston et al., 2009). Results obtained
in animal models support the hypolipemic and vasoprotective
eﬀects of Bergamot constituents such as various bioﬂavonoids
(Choe et al., 2001; Mollace et al., 2008), indicating that Citrus
ﬂavonoids might prevent atherosclerosis (Yu et al., 2005; Miceli
et al., 2007).
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FIGURE 4 | Schematic representation of potential lipid lowering effect of Bergavit R© (Bergamot-derived flavonoids: 150 mg of flavonoids, with 16% of
neoeriocitrin, 47% of neohesperidin and 37% of naringin, daily). Several mechanisms may concur to regulate lipid homeostasis. Flavonoids may lead to an
increase of lipid consumption via activation of mitochondria oxidation and at the same time flavonoids decrease very low-density lipoproteins (VLDL) synthesis. Other
potential mechanisms include increased LDL receptor gene transcription via protein kinase C (PKC) activation and increased membrane translocation of this receptor
via peroxisome proliferator-activated receptors gamma (PPAR-γ) activation. AMPK-α, adenosine monophosphate-activated protein kinase alpha; CPT1, carnitine
palmitoyltransferase 1; HNF4, hepatocyte nuclear factor 4; SREBP-1, sterol regulatory element-binding protein 1.
Potential limitations of the present study include the absence
of a control (placebo) group, while its strengths include full
treatment adherence as well as the blinded measurements
of biochemical parameters, lipoprotein subclasses, as well as
a blinded manner in assessing cIMT. We used high-quality
methodology to assess the full spectrum of LDL subclasses and
for the ﬁrst time demonstrated beneﬁcial eﬀects on subclinical
atherosclerosis.
CONCLUSION
This is the ﬁrst study investigating the eﬀect of Bergavit R©
supplementation on cardio-metabolic risk in dyslipidemic
subjects. Bergavit R© supplementation signiﬁcantly lowered
plasma lipids (TC, TG, and LDL-C) and improved the
lipoprotein proﬁle by decreasing atherogenic small, dense
LDL particles. Of great clinical signiﬁcance is that Bergavit R©
signiﬁcantly reduced cIMT after 6 months of supplementation.
Consequently, Bergavit R© may represent a safe, alternative
therapeutic approach, especially in subjects suﬀering from
statin intolerance, that may contribute to a diminished
risk for atherosclerosis. These ﬁndings shed a new light
on the potential use of Bergamot-extract supplements in
the prevention and/or reduction of overall cardiometabolic
risk.
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